Previous close | 71.91 |
Open | 71.29 |
Bid | 71.25 x 800 |
Ask | 72.26 x 800 |
Day's range | 70.77 - 72.50 |
52-week range | 61.91 - 84.86 |
Volume | |
Avg. volume | 1,507,588 |
Market cap | 16.051B |
Beta (5Y monthly) | 0.64 |
PE ratio (TTM) | 16.94 |
EPS (TTM) | 4.26 |
Earnings date | 31 Oct 2022 - 04 Nov 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 88.75 |
Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.
Incyte (INCY) delivered earnings and revenue surprises of 27.85% and 11.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
WILMINGTON, Del., August 02, 2022--Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs